ArticleJournal of the American Heart Association2025
Evaluation of Blood Pressure Control, Medication Adherence, and Therapeutic Inertia in US Patients With Hypertension Prescribed Multiple Antihypertensives.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study.Advances in therapy · 2026Article
- Triple and quadruple combination antihypertensive therapy in untreated individuals.Journal of human hypertension · 2026Review
- Global disparities in realized stroke prevention attributable to antihypertensive treatment: a population-level analysis of 198 countries, 1990-2019.European journal of epidemiology · 2026Article
- Application of AI in Hypertension Health Education: Scoping Review.Journal of medical Internet research · 2026Article
- AMCP Market Insights: Getting to the heart of hard-to-control hypertension in managed care.Journal of managed care & specialty pharmacy · 2026Article
- Retrospective comparison of ChatGPT-4 treatment recommendations with real-world physician management in newly diagnosed hypertension: a single-centre study.Frontiers in cardiovascular medicine · 2026Article
- Hypertension control within the HEARTS program of south-west Trinidad: a longitudinal mixed-effects analysis.Revista panamericana de salud publica = Pan American journal of public health · 2026Article
- Knowledge of Hypertension and Self-Blood Pressure Measurement Skills in Spain.Journal of primary care & community healthObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFailure to control blood pressure (BP) despite multiple prescribed antihypertensive medications (AHMs) is widespread and leads to worse clinical outcomes. Recent changes to BP targets in US clinical guidelines require an updated evaluation of BP control including evaluations of nonadherence and therapeutic inertia.
methodsWe leveraged clinical and insurance data sourced from >50 US health care organizations to identify >500 000 patients with established hypertension (>15-month history) concurrently prescribed ≥3 AHM classes in 2019. We characterized the prevalence of uncontrolled hypertension and describe patterns of nonadherence (lack of AHM fills covering >80% of days) and therapeutic inertia (failure to escalate AHM for patients persistently out of BP control). We described the associations with factors including race, ethnicity, sex, and insurance.
resultsAmong 565 737 patients prescribed ≥3 AHMs, 37.7% met the recommended BP target of <130/80 mm Hg. Black race (odds ratio [OR], 0.71 [95% CI, 0.70-0.73]) and uninsured status (OR, 0.81 [95% CI, 0.76-0.86]) were most associated with lack of BP control relative to White or commercially insured patients. In a subset of insured patients, nonadherence occurred in 52.7%, although BP control remained poor among adherent patients (43.0% versus 39.4% for nonadherent). Therapeutic inertia was widespread; 64.5% of patients persistently above the BP target had no medication escalation within 18 months.
conclusionsAn evaluation of a US-based, large, real-world patient cohort demonstrates that most patients prescribed ≥3 AHMs fail to achieve the recommended BP target of <130/80, and both medication nonadherence and therapeutic inertia are widespread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.